Skip to main content
SpringerLink
Log in

Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment

  • Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Our ability to assess and stratify atherosclerotic disease risk in patients is evolving. Recent advances in advanced lipid testing have created opportunities for clinical application of novel biomarkers.

Recent Findings

Until recently, LDL-C has served largely as the singular biomarker of ASCVD and guide for decisions in treatment for high-risk groups. There are important evolutions in the measurement of LDL-C but even still, the pathogenesis of atherosclerosis and ASCVD is not solely driven by LDL-C. As atherosclerosis is driven by multiple complex pathways including inflammation, it is important to expand our focus beyond LDL-C and utilize multiple biomarkers in the assessment of this disease process.

Summary

Non-HDL, ApoB, LDL-P, Lp(a), and hsCRP are unique tools to aid in cardiac risk evaluation, especially in higher risk patients, though not limited to this population. A multifaceted approach to advanced lipid testing with novel biomarkers will enhance comprehensive ASCVD risk assessments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •   Of importance •• Of major importance

  1. • Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016;67:353–61. The IMPROVE-IT trial included 18,144 patients who were randomized to receive intensive lipid-lowering therapy (ezetimibe/statin) or placebo/statin. The intensive treatment group had fewer MIs and strokes which led to significant reduction in events following acute coronary syndrome. Overall, this suggests improved clinical outcomes with aggressive lipid-lowering therapies.

    Article  CAS  Google Scholar 

  2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.

    Article  CAS  Google Scholar 

  3. • Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207. This clinical trial demonstrates the utility of CRP as an atherogenic biomarker. In healthy patients who had LDL-C < 130 but CRP > 2, treatment with rosuvastatin was associated with lower incidence of major cardiovascular events over median follow up of 1.9 years.

    Article  CAS  Google Scholar 

  4. • Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71. This randomized, double-blind trial tested the effect of an immune-modulating antibody, canakinumab, on reduction in cardiovascular events. This was a positive trial and as such demonstrated that cardiovascular risk is related to inflammation which may suggest markers of inflammation like CRP, if elevated, may be heralds of future ASCVD.

    Article  CAS  Google Scholar 

  5. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park J-G, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017;2:547–55.

    Article  Google Scholar 

  6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.

    Article  CAS  Google Scholar 

  7. • Schwartz GG, Szarek M, Bittner VA, et al. Lipoprotein(a) and Benefit of PCSK9 Inhibition in patients with nominally controlled LDL cholesterol. J Am Coll Cardiol. 2021;78:421–33. This trial demonstrated benefit of treatment goals beyond achieving target LDL-C. In the trial, patients who had recent ACS but accomplished an LDL-C level near 70 mg/dl on statin therapy still gained additional benefit with PCKS9 inhibitor therapy if Lp(a) was elevated.

    Article  CAS  Google Scholar 

  8. •• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–92. This trial established an association between elevated Lp(a) and cardiovascular events regardless of LDL-C levels. Additionally, it showed a reduction in Lp(a) levels when evolucumab was used as treatment.

    Article  Google Scholar 

  9. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004–13.

    Article  CAS  Google Scholar 

  10. Orakzai SH, Nasir K, Blaha M, Blumenthal RS, Raggi P. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis. 2009;202:289–95.

    Article  CAS  Google Scholar 

  11. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. 1990;36:15–9.

    Article  CAS  Google Scholar 

  12. Jialal I, Inn M, Siegel D, Devaraj S. Underestimation of low density lipoprotein-cholesterol with the friedewald equation versus a direct homogenous low density lipoprotein-cholesterol assay. Lab Med. 2017;48:220–4.

    Article  Google Scholar 

  13. Wilson PW, Zech LA, Gregg RE, Schaefer EJ, Hoeg JM, Sprecher DL, Brewer HB Jr. Estimation of VLDL cholesterol in hyperlipidemia. Clin Chim Acta. 1985;151:285–91.

    Article  CAS  Google Scholar 

  14. Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel statement, Main Text. Curr Vasc Pharmacol. 2019;17:498–514.

    Article  CAS  Google Scholar 

  15. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061–8.

    Article  CAS  Google Scholar 

  16. Sampson M, Ling C, Sun Q, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5:540–8.

    Article  Google Scholar 

  17. Sajja A, Park J, Sathiyakumar V, et al. Comparison of methods to estimate low-density lipoprotein cholesterol in patients with high triglyceride levels. JAMA Netw Open. 2021;4: e2128817.

    Article  Google Scholar 

  18. Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, Tsimikas S. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79:1035–46.

    Article  CAS  Google Scholar 

  19. Packard CJ. Determinants of achieved LDL cholesterol and “non-HDL” cholesterol in the management of dyslipidemias. Curr Cardiol Rep. 2018;20:60.

    Article  Google Scholar 

  20. Verbeek R, Hovingh GK, Boekholdt SM. Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol. 2015;26:502–10.

    Article  CAS  Google Scholar 

  21. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337–45.

    Article  Google Scholar 

  22. Carr SS, Hooper AJ, Sullivan DR, Burnett JR. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51:148–54.

    Article  CAS  Google Scholar 

  23. Trialists CT, Collaborators (CTT), Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.

    Article  Google Scholar 

  24. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77:1439–50.

    Article  CAS  Google Scholar 

  25. Chen SH, Yang CY, Chen PF, Setzer D, Tanimura M, Li WH, Gotto AM Jr, Chan L. The complete cDNA and amino acid sequence of human apolipoprotein B-100. J Biol Chem. 1986;261:12918–21.

    Article  CAS  Google Scholar 

  26. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR, AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55:407–19.

    Article  Google Scholar 

  27. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287–95.

    Article  Google Scholar 

  28. Sniderman AD, Bergeron J, Frohlich J. Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial. CMAJ. 2001;164:44–7.

    CAS  Google Scholar 

  29. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129:553–61.

    Article  CAS  Google Scholar 

  30. Welsh C, Celis-Morales CA, Brown R, et al. Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease. Circulation. 2019;140:542–52.

    Article  CAS  Google Scholar 

  31. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–9.

    Article  CAS  Google Scholar 

  32. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012;110:1468–76.

    Article  CAS  Google Scholar 

  33. Langlois MR, Nordestgaard BG, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020;58:496–517.

    Article  CAS  Google Scholar 

  34. Kohli-Lynch CN, Thanassoulis G, Moran AE, Sniderman AD. The clinical utility of apoB versus LDL-C/non-HDL-C. Clin Chim Acta. 2020;508:103–8.

    Article  CAS  Google Scholar 

  35. Castañer O, Pintó X, Subirana I, Amor AJ, Ros E, Hernáez Á, et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76:2712–24.

    Article  Google Scholar 

  36. Goliasch G, Wiesbauer F, Blessberger H, Demyanets S, Wojta J, Huber K, et al. Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. J Clin Lipidol. 2015;9:801-806.e1.

    Article  Google Scholar 

  37. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–70.

    Article  Google Scholar 

  38. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967;276:94–103 contd.

  39. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811–22.

    Article  CAS  Google Scholar 

  40. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556–63.

    Article  CAS  Google Scholar 

  41. Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med. 2009;150:474–84.

    Article  Google Scholar 

  42. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PWF, D’Agostino RB. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. J Clin Lipidol. 2007;1:583–92.

    Article  Google Scholar 

  43. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5:105–13.

    Article  Google Scholar 

  44. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis. 2012;225:444–9.

    Article  CAS  Google Scholar 

  45. Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis. 2014;235:585–91.

    Article  CAS  Google Scholar 

  46. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009;32:1087–91.

    Article  CAS  Google Scholar 

  47. Rosenson RS, Underberg JA. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther. 2013;27:465–79.

    Article  CAS  Google Scholar 

  48. Sniderman AD. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J Clin Lipidol. 2008;2:36–42.

    Article  Google Scholar 

  49. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJP, Bittner V, Fruchart J-C. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventS. N Engl J Med. 2007;357:1301–10.

    Article  CAS  Google Scholar 

  50. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma TG and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757–63.

    Article  CAS  Google Scholar 

  51. Folse HJ, Goswami D, Rengarajan B, Budoff M, Kahn R. Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study. Atherosclerosis. 2014;236:154–61.

    Article  CAS  Google Scholar 

  52. Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74:2982–94.

    Article  CAS  Google Scholar 

  53. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57:1339–59.

    Article  CAS  Google Scholar 

  54. Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J. 2019;71:99–112.

    Article  Google Scholar 

  55. • Paré G, Çaku A, McQueen M, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139:1472–82. This study highlighted differences in Lp(a) concentration between ethnic groups with highest burden within South Asian and Latin American populations. As Lp(a) was shown to be associated with increased risk for MI, it may be of higher clinical value in these sub-populations of patients.

    Article  Google Scholar 

  56. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117:176–84.

    Article  CAS  Google Scholar 

  57. Collaboration ERF, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–23.

    Article  Google Scholar 

  58. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55:2160–7.

    Article  CAS  Google Scholar 

  59. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28.

    Article  CAS  Google Scholar 

  60. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, König P, Dieplinger H. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027–36.

    Article  CAS  Google Scholar 

  61. Laschkolnig A, Kollerits B, Lamina C, et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res. 2014;103:28–36.

    Article  CAS  Google Scholar 

  62. Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): when and how to measure it. Ann Clin Biochem. 2021;58:16–21.

    Article  CAS  Google Scholar 

  63. Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on lipoprotein(a): a call to action. Atherosclerosis. 2019;291:62–70.

    Article  CAS  Google Scholar 

  64. Kunzmann K. What’s next for lipoprotein(a) lowering agent SLN360. In: HCPLive. 2022. https://www.hcplive.com/view/next-for-lipoprotein-a-lowering-agent-sln360. Accessed 12 Apr 2022.

  65. Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J. 2020;13:753–7.

    Article  CAS  Google Scholar 

  66. Kervinen H, Palosuo T, Manninen V, Tenkanen L, Vaarala O, Mänttäri M. Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J. 2001;141:580–5.

    Article  CAS  Google Scholar 

  67. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813–8.

    Article  CAS  Google Scholar 

  68. Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109:1349–53.

    Article  Google Scholar 

  69. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen T-P, Salonen JT. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur Heart J. 2005;26:1783–9.

    Article  CAS  Google Scholar 

  70. •• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143. This reference is the most recent practice guidelines for atherosclerotic disease and lipid management from the American College of Cardiology and American Heart Association.

    Google Scholar 

  71. •• Mach F, Baigent C, Catapano AL. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of. Eur Heart J. 2020. This reference is the most recent practice guideline for atherosclerotic disease and lipid management from the European Society of Cardiology and European Atherosclerosis Society.

  72. •• Wilson PWF, Jacobson TA, Martin SS, Jackson EJ, Le N-A, Davidson MH, Vesper HW, Frikke-Schmidt R, Ballantyne CM, Remaley AT. Lipid measurements in the management of cardiovascular diseases: practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021;15:629–48. This reference is the most recent guidelines for lipid management from the National Lipid Association independent of ACC/AHA.

    Article  Google Scholar 

  73. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338–67.

    Article  Google Scholar 

  74. •• Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37:1129–50. This reference is the most recent practice guidelines for atherosclerotic disease and lipid management from the Canadian Cardiovascular Society.

    Article  Google Scholar 

  75. Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD, Reiss AB. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites. 2021. https://doi.org/10.3390/metabo11100690

Download references

Author information

Authors and Affiliations

  1. Internal Medicine UC San Diego, La Jolla, 200 W. Arbor Drive, San Diego, CA, 92103-8425, USA

    Alexandra Vaio Sykes

  2. UC San Diego School of Medicine, La Jolla, San Diego, CA, USA

    Neeja Patel

  3. Family Medicine UC San Diego, La Jolla, San Diego, CA, USA

    Danielle Lee

  4. Cardiovascular Medicine, UC San Diego, La Jolla, San Diego, CA, USA

    Pam R. Taub

Authors
  1. Alexandra Vaio Sykes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neeja Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Danielle Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pam R. Taub
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra Vaio Sykes.

Ethics declarations

Conflict of Interest

Pam R Taub, MD is a consultant to Amgen, Bayer, Boehringer-Ingelheim, Esperion Therapeutics, Medtronic, Novartis, Novo-Nordisk, and Sanofi. Dr. Taub also reports stock or stock options for Epirium Bio (but no payments). The other authors have nothing to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lipid Abnormalities and Cardiovascular Prevention.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sykes, A.V., Patel, N., Lee, D. et al. Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment. Curr Cardiol Rep 24, 1647–1655 (2022). https://doi.org/10.1007/s11886-022-01775-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-022-01775-5

Keywords

Search

Navigation